Positive interim safety results from the first two dose escalation cohorts, referred to as Cohorts 1 and 2, were reported in 4Q 2024. Today’s update is focused on safety and molecular findings from ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first patient dosed in a visceral tumor ...

Sutro Biopharma (STRO) announced an update on their ongoing clinical study. Study Overview: Sutro Biopharma is conducting a Phase 1 open-label study titled A Phase 1 Open-Label Study to Evaluate ...

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment ...

Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...